Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
% y% i" o1 k- l! A& h' Y
a3 Y( n l; U( q0 M% o* D. b; ?1 |; J: Q
Sub-category:
# a4 x$ {2 {! OMolecular Targets 8 j7 R$ [3 P* J; g. ]" Z5 N
3 F# ?1 e* f* E6 ^. [! K& F# L
! @# H5 ?' |; P
Category:
9 ?( W( \0 i' dTumor Biology ; n2 z" S% I2 M) \/ a
' _+ g3 I. u* U7 E) r/ k: ^; E; X! e# g2 o7 Q( Q
Meeting:: Q: d! Q3 N. Z' W% D- ^" r
2011 ASCO Annual Meeting 5 r0 U) T3 g- C' i
( j, a4 t8 e0 @* U n9 n
# a' ?3 T: t8 |: f3 {Session Type and Session Title:
$ Z: |6 g4 a+ q4 L! h: d( {. EPoster Discussion Session, Tumor Biology
7 `" G0 r9 x {2 |# O* G% I
0 @1 ~6 z: X7 l7 U1 s% K- x; | O9 o* a6 J8 c
Abstract No:
: H, O! g1 o; ]' @! z3 u3 ~10517
, Q }5 ~1 r. Z1 e$ M& i. R
6 Y/ w! V) U C& d" A d; Z
& R; H) ?4 V* N' ~5 mCitation:
. n k& c% n8 x6 ?4 h* BJ Clin Oncol 29: 2011 (suppl; abstr 10517)
- @5 O4 N* H1 v, @1 z% {+ l' A" U
. x+ Y4 e( j7 L! a7 X/ o) M7 |1 F5 }( T6 \% W/ D
Author(s):9 d7 A. U6 W& ]' J K; f6 E5 N
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
; ]( Q: f! t* H& b$ W$ z& X. _' m8 z! B. G2 ~
F3 s4 q) r+ r; W/ T9 s! E& Z; y6 X, q& p- q( k+ j
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings." o; i( R% J; ^+ P. \/ K
! f; Y3 a: |; N5 A5 q# {Abstract Disclosures
5 `) p4 t$ Y5 @2 j1 O+ M- r3 t1 z# Y7 m# g
Abstract:; f! Q+ K# ?4 J/ s2 `
w3 K2 L8 G+ p5 j: Y) b' @4 G( W9 C0 Z( W
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 G( O* O- Y1 [" l" F
; h1 `. r; y+ M) f! f1 h* B
5 _ B$ Q& m" _; B, [+ Z5 ]4 y |
显身卡
